Novartis eyes Alcon's devices-and-drugs "package" to diversify
This article was originally published in Clinica
Executive Summary
In what could be the biggest deal to date in the history of the Swiss economy, Basel-based pharma giant Novartis is looking to acquire Alcon, the leading eyecare company, in a deal worth up to $39bn.